Related Experiment Video
Updated: Jun 17, 2026
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
[Validation study of KRAS mutation in colorectal cancer]
1Semmelweis Egyetem I. sz. Patológiai és Kísérleti Rákkutató Intézet 1085 Budapest Ulloi út 26. kopper@korb1.sote.hu
Abstract:
There is no doubt that molecular targeted therapy has increasing importance in clinical oncology. Markers related to the molecular targets can help in the prediction of the antitumoral effect as well as in the positive or negative selection of patients. Such a marker is KRAS, since its mutation inhibits the effectiveness of anti-EGFR monoclonal antibodies in the treatment of advanced and/or metastatic colorectal cancer. To identify KRAS mutations different methods and techniques are available. A voluntarily performed study served to control the validity of our methods. As a result the 7 partcipating laboratories approached but not fulfilled (except one) the criteria set by EPS. A joint discussion helped to call the attention to some technical and financial problems. The key conditions to recognize mutational status of KRAS or other similar markers are the accredited laboratory for molecular diagnostics and the validated method. The improvement of the quality of such techniques is supported by the fact that more and more drugs can be used only after the obligatory measurement of relevant molecular target(s).
Insights
KRAS mutation testing is crucial for predicting colorectal cancer treatment effectiveness. A study revealed that most participating labs did not meet quality standards for KRAS mutation analysis, highlighting the need for accredited labs and validated methods.
Area of Science:
- Oncology
- Molecular Diagnostics
- Genetics
Background:
- Molecular targeted therapy is vital in clinical oncology.
- Biomarkers like KRAS predict treatment response and guide patient selection.
- KRAS mutations impact anti-EGFR monoclonal antibody efficacy in metastatic colorectal cancer.
Purpose of the Study:
- To assess the validity and reliability of KRAS mutation detection methods.
- To identify challenges in molecular diagnostic testing for KRAS mutations.
Main Methods:
- A voluntary study involving 7 laboratories was conducted.
- Laboratories performed KRAS mutation detection using their standard methods.
- Results were compared against established quality criteria.
Main Results:
- Only one of the seven participating laboratories met the set quality criteria (EPS).
- Significant technical and financial challenges were identified.
- The study underscored variability in KRAS mutation analysis across different labs.
Conclusions:
- Accredited laboratories and validated methods are essential for accurate KRAS mutational status determination.
- Improving the quality of molecular diagnostic techniques is critical.
- Mandatory testing of molecular targets is increasingly required for targeted cancer therapies.
Related Concept Videos
02:38The Ras Gene
Ras is a superfamily...
01:24Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...